Egypt’s Central Administration for Pharmaceutical Affairs (CAPA), the country’s medical device market regulator, has published a series of updates and amendments to its registration requirements on its website.
Among the more significant changes are:
In addition, CAPA requires that the first shipments of all sterile medical devices from either reference or non-reference countries must be submitted for analysis by the National Organization for Drug Control and Research before those products can be sold in the Egyptian market.
CAPA has also loosened requirements for technical file submissions. Registrants no longer have to include biocompatibility test reports and stability studies, and legalization of declarations of conformity is no longer required.
By easing some requirements, expanding its list of reference countries and accelerating some registration deadlines, CAPA has taken steps to simplify the medical device approval process in Egypt.